OKYO Pharma Ltd (OKYO) ORD NPV
- Add to watchlist
- This stock can be held in a
Business summary
OKYO Pharma Limited is a United Kingdom-based preclinical biopharmaceutical company. The Company is focused on developing an approach to dry eye care and ocular pain that is developing a lipidated chemerin-peptide drug candidate, OK-101, designed to target an ocular receptor controlling inflammation and ocular pain. The Company’s principal activity is to develop drugs for inflammatory dry eye diseases and chronic pain by targeting G protein-coupled receptors (GPCRs). The Company operates through the research and development of biotechnological and pharmaceutical products segment. The Company’s technologies include Chemerin Receptor, OK-101 Drug Candidate and Preclinical Data. Its membrane anchored peptide (MAP) technology enabled the development of OK-101. Its drug candidate, OK-101, consists of a 10-mer C-terminal chemerin peptide sequence, a linker component, and an anchoring lipid domain. The Company’s wholly owned subsidiary is OKYO Pharma US Inc.
Contact details
Important dates
General stock information
- Short code:
- OKYO
- ISIN:
- GG00BMFG5F62
- Market cap:
- $47.63 million
- Shares in issue:
- 59.30 million
- Sector:
- Biotechnology
- Exchange:
- NASDAQ
- Country:
- Guernsey
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.